Sequana Medical NV (EBR:SEQUA)
Belgium · Delayed Price · Currency is EUR 0.6110
0.00 (0.00%)
Apr 28, 2026, 5:35 PM CET
Sequana Medical NV Company Description
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure.
The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure.
It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Sequana Medical NV
| Country | Belgium |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Ian Crosbie |
Contact Details
Address: Kortrijksesteenweg 1112 Gent Belgium | |
| Phone | 32 9 292 8065 |
Stock Details
| Ticker Symbol | SEQUA |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974340722 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Ian Crosbie | Chief Executive Officer and Executive Director |
| Kirsten Van Bockstaele | Chief Financial Officer |
| Dr. Gijs Klarenbeek M.D. | MD and Chief Medical Officer |
| Martijn Blom | Chief Commercial Officer |
| Mark Singer | Head of U.S. Commercial |